Clinical Trial Detail

NCT ID NCT02913196
Title Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With mCRPC
Recruitment Recruiting
Gender male
Phase Phase I
Variant Requirements No
Sponsors Weill Medical College of Cornell University
Indications

prostate adenocarcinoma

Therapies

Abiraterone + Apalutamide + Docetaxel + Prednisone

Age Groups: child adult senior

No variant requirements are available.